Benign Conditions

"A global consensus on standardization of terminology, separation of LUTS vs pain for outcome, HL positivity and negativity, markers for disease, and the role of new interventions for local vs systemic therapy is needed," writes Gopal H. Badlani, MD.

Follow Urology Times' coverage of the full-day FDA advisory committee meeting regarding Iterum Therapeutics' new drug application for oral sulopenem for uncomplicated urinary tract infection.

"Teixobactin, and more broadly, the iChip approach to novel antibiotic discovery, is an exciting development in infection control," write Philip Abbosh, MD, PhD, and Kate Gessner, MD, PhD.

“I think in terms of symptom elicitation, it's important to be systematic so that we don't shortchange certain populations when we try to figure out what their symptoms are,” says Briony K. Varda, MD, MPH.

"The objective of this study was to assess baseline knowledge about urinary tract infections, interest in health resources, and platform preferences for health information acquisition and dissemination," says Stephanie Gleicher, MD.

"I can say that I do see a vast number of different types of patient populations," says Adity Dutta, MSN, AGACNP-BC.

"I think these findings are critical in helping us craft educational resources that would be easily understood and easily disseminated by trusted health care providers," says Stephanie Gleicher, MD, MPH.

"This study reinforces our role as physicians to guide patients away from costly supplements with little or no benefit," said Wai Lee, MD.

"I think having success with that in humans will make [radiofrequency ablation] very, very valuable for the practicing urologist that can be done in the clinic without much training or anything like that," says Gamal M. Ghoniem, MD, FACS, ABU/FPMRS.

"Glean technology is a very brilliant technology that has been developed for basically portable urodynamics," says Zhina Sadeghi, MD.

"We...found that about 50% of women felt like infections are caused by lack of cleanliness and tight-fitting clothes," says Stephanie Gleicher, MD.

"What we believe is happening is women are seeking the help of female urologists, and therefore, because of the nature of the condition, the female urologists are absorbing the burden of the care of these patients, particularly the non-billable burden," says Debra L. Fromer, MD.

"With regards to barriers to attaining health information, we found that a lot of women reported that medical language is just too complex," says Stephanie Gleicher, MD, MPH.

"We found that during the 5-year study period, the total number of claims for vaginal estrogen, the number of prescribers, and the number of beneficiaries decreased," says Alexandra Tabakin, MD.

Glenn T. Werneburg, MD, PhD, discusses 2 abstracts from the 2024 SUFU Winter Meeting.

The predictive models identified the number of previous UTI episodes, prior β-lactam nonsusceptibility, prior fluoroquinolone treatment, Census Bureau region (particularly in the South), and race as key predictors of having a non-susceptible isolate to 3 or more antibiotic classes.

"In our professional life, awareness of our bias in seeing patients based on their weight, color, age, literacy level, or social status is evident," writes Gopal H. Badlani, MD.

"We did discuss a couple of future research ideas, a number of which would have been controlling for those potential factors we thought could contribute to the increased UTI risk that we were not able to control for in the study like loss of commensal bacteria or anything of that nature," says David Gilbert.

Despite varied preferences for surgical vs medical treatments, most participants expressed an interest in seeking treatment for PFDs.

"Results from these trials show that giving physicians an alert informing them of their patient’s actual risk for antibiotic resistance can help them choose the best antibiotic and reduce extended-spectrum antibiotic use,” says Shruti Gohil, MD, MPH.

The approval is based on 3 clinical trials evaluating the efficacy of different pivmecillinam dosing regimens in comparison with either placebo, another oral antibacterial drug, or ibuprofen.

"I think the main question is just how to disseminate this information. Obviously, there's a huge need," says Megan S. Bradley, MD.

"We found that only about 8% of people in this national survey of over 500 participants had heard of asymptomatic bacteriuria," says Megan S. Bradley, MD.

"Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe," says Bob Yang, MBBS, FRCS.